Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027 JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to

#JBIO Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/JBIO/jade-bioscienc...

Jade Biosciences Announces $45 Million Private Placement Jade Biosciences (Nasdaq: JBIO) entered a securities purchase agreement with BB Biotech for a $45 million private placement, selling 3,214,286 shares of common stock at $14.00 per share. The private placement is expected to close on or about December 16, 2025, subject to customary closing conditions.The company said it intends to use net proceeds to fund research and development, general corporate expenses, and working capital. The sale is a private transaction and the shares are unregistered; Jade agreed to file a registration statement with the SEC to register resale of the shares under a registration rights agreement.

#JBIO Jade Biosciences Announces $45 Million Private Placement

www.stocktitan.net/news/JBIO/jade-bioscienc...

#JBIO Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/JBIO/jade-bioscienc...

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025 Jade Biosciences (Nasdaq: JBIO) will present new preclinical safety and translational data for JADE101 at ASN Kidney Week 2025 in Houston, Nov 5–9, 2025. JADE101 is an anti-APRIL monoclonal antibody in development for immunoglobulin A nephropathy (IgAN) and is engineered for subcutaneous dosing based on differentiated preclinical PK/PD in non-human primates.The company is conducting a Phase 1 healthy volunteer trial of JADE101, with interim data expected in the first half of 2026. Two poster presentations are scheduled on Nov 8, 2025, 10:00 AM–12:00 PM CT: SA-PO0255 (nonclinical safety) and SA-PO0272 (translational framework), presented by Ashley McCord and Brandon Gufford.

#JBIO Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

www.stocktitan.net/news/JBIO/jade-bioscienc...

Jade Biosciences Announces $135 Million Private Placement Jade Biosciences (Nasdaq: JBIO) announced a private placement expected to raise approximately $135 million in gross proceeds via a PIPE financing, subject to customary closing conditions with an expected close on or about October 8, 2025. The transaction sells 13,368,164 shares at $9.14 and 1,402,092 pre-funded warrants at $9.1399 each (exercise price $0.0001).After issuance, there will be about 67.4 million shares and equivalents outstanding. The company said net proceeds plus existing cash are expected to fund operations into 1H 2028. Placement agents and a registration rights agreement were disclosed.

#JBIO Jade Biosciences Announces $135 Million Private Placement

www.stocktitan.net/news/JBIO/jade-bioscienc...

Jade Bio's New IgA Nephropathy Drug Shows Superior Binding Power, Phase 1 Trial Starts Q3 Preclinical data reveals JADE101's ultra-high APRIL binding affinity is 750x stronger than competitor. $220.9M cash runway extends through 2027. Phase 1 trial begins Q3. Get insights.

#JBIO Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/JBIO/jade-bioscienc...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new uptrend in average directional index, Tue Jun 24th - #MPU #SWIN #STI #MIND #UNTY #SMLR #LILA #JBIO #IRMD #COMM #OPY #KW #GTN #EVH - More: crystalequityresearch.com/SmCpStr/ - #smallcap

New IgA Nephropathy Drug Shows 750x Better Binding: JADE101 Outperforms Competitors in Key Metrics Breakthrough preclinical data reveals JADE101's superior 27-day half-life and 100+ days of sustained IgA suppression for nephropathy treatment. See complete results.

#JBIO Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

www.stocktitan.net/news/JBIO/jade-bioscienc...

Jade Biosciences Secures Massive $300M Funding After Nasdaq Debut, First Clinical Trial Set for 2025 Fresh off Nasdaq merger, Jade Biosciences secures $300M backing for autoimmune therapies pipeline. Key clinical milestone ahead in 2025. See full roadmap.

#JBIO Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/JBIO/jade-bioscienc...